CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells

Radiotherapy and Oncology

Volumn 110, Issue 3, 2014, Pages 538-545

  Desai, Amar ^a,b   Webb, Bryan ^b   Gerson, Stanton L ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Cancer stem cells; CD133; Radiation resistance

Indexed keywords

BRCA1 PROTEIN; CD133 ANTIGEN; DNA; EXO1 PROTEIN; KU ANTIGEN; MRE11 PROTEIN; PROTEIN; PROTEIN MSH2; RAD51 PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; RAD51 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EXPLORATORY RESEARCH; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IONIZING RADIATION; LUNG CANCER; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE DISTRIBUTION; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; CANCER STEM CELL; GENETICS; LUNG NEOPLASMS; PHYSIOLOGY; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL LINE;

ANTIGENS, CD; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; NEOPLASTIC STEM CELLS; PEPTIDES; RAD51 RECOMBINASE; RADIATION TOLERANCE;

EID: 84899559860     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.10.040     Document Type: Article

References (39)

1. M. Al-Hajj et al. Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci U S A 100 2003 3983 3988
2. P. Dalerba et al. Phenotypic characterization of human colorectal cancer stem cells Proc Natl Acad Sci U S A 104 2007 10158 10163
3. A. Eramo et al. Identification and expansion of the tumorigenic lung cancer stem cell population Cell Death Differ 15 2008 504 514
4. C. Li et al. Identification of pancreatic cancer stem cells Cancer Res 67 2007 1030 1037
5. S.K. Singh et al. Identification of human brain tumour initiating cells Nature 432 2004 396 401
6. C.E. Eyler, and J.N. Rich Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis J Clin Oncol 26 2008 2839 2845
7. Y. Yu, G. Ramena, and R.C. Elble The role of cancer stem cells in relapse of solid tumors Front Biosci (Elite Ed) 4 2012 1528 1541
8. H. Zhang, and S.Y. Li Research progression of CD133 as a marker of cancer stem cells Chin J Cancer 29 2010 243 247
9. X. Yu et al. CD133, stem cells, and cancer stem cells: myth or reality? Curr Colorectal Cancer Rep 7 2011 253 259
10. S. Bao et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 2006 756 760
11. E.R. Blazek, J.L. Foutch, and G. Maki Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia Int J Radiat Oncol Biol Phys 67 2007 1 5
12. X. Wang et al. Chk1 knockdown confers radiosensitization in prostate cancer stem cells Oncol Rep 28 2012 2247 2254
13. M. Ropolo et al. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures Mol Cancer Res 7 2009 383 392
14. C. Dittfeld et al. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116 Radiother Oncol 92 2009 353 361
15. V. Tirino et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer Eur J Cardiothorac Surg 36 2009 446 453
16. K. Shien et al. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy Lung Cancer 77 2012 162 167
17. H. Iida et al. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2 Int J Oncol 40 2004 71 79
18. G. Bertolini et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment Proc Natl Acad Sci U S A 106 2009 16281 16286
19. Y.P. Liu et al. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling Cancer Res. 73 2013 406 416
20. K.K. Khanna, and S.P. Jackson DNA double-strand breaks: signaling, repair and the cancer connection Nat Genet 27 2001 247 254
21. A. Sancar et al. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints Annu Rev Biochem 73 2004 39 85
22. L. Krejci et al. Homologous recombination and its regulation Nucleic Acids Res 40 2012 5795 5818
23. D. Schild, and C. Wiese Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability Nucleic Acids Res 38 2010 1061 1070
24. C.M. Hine, A. Seluanov, and V. Gorbunova Use of the Rad51 promoter for targeted anti-cancer therapy Proc Natl Acad Sci U S A 105 2008 20810 20815
25. J.C. Ko et al. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells Carcinogenesis 29 2008 1448 1458
26. N. Tomimatsu et al. Exo1 plays a major role in DNA end resection in humans and influences double-strand break repair and damage signaling decisions DNA Repair (Amst) 11 2012 441 448
27. V. Garcia et al. Bidirectional resection of DNA double-strand breaks by Mre11 and Exo1 Nature 479 2011 241 244
28. J. Mihatsch et al. Selection of radioresistant tumor cells and presence of ALDH1 activity in vitro Radiother Oncol 99 2011 300 306
29. Mizugaki H, et al. CD133 expression: a potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol. 2013; epub ahead of print.
30. M.S. Tsai et al. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells J Pharmacol Exp Ther 335 2010 830 840
31. D. Davidson et al. Small molecules, inhibitors of DNA-PK, targeting DNA repair, and beyond Front Pharmacol 4 2013 5
32. K.V. Clark-Knowles, A.M. O'Brien, and J.I. Weberpals BRCA1 as a therapeutic target in sporadic epithelial ovarian cancer J Oncol 2010 891059
33. J. Yang et al. Expression of DNA-PKcs and BRCA1 as prognostic indicators in nasopharyngeal carcinoma following intensity-modulated radiation therapy Oncol Lett 5 2013 1199 1204
34. Z. Li et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells Cancer Cell 15 2009 501 513
35. N. Chan et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance Cancer Res 68 2008 605 614
36. R.S. Bindra, and P.M. Glazer Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia Oncogene 26 2007 2048 2057
37. D. Trachootham, J. Alexandre, and P. Huang Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8 2009 579 591
38. K. Moitra, H. Lou, and M. Dean Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development Clin Pharmacol Ther 89 1996 491 502
39. H. Sartelet et al. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway Histopathology 60 2012 1144 1155